Seclidemstat

Research use only, not for human use.

Seclidemstat (SP-2577, SP2577) is a potent, selective LSD1 inhibitor with IC50 of 127 nM, reduces tumor volume in vivo.

Seclidemstat (SP-2577, SP2577) is a potent, selective LSD1 inhibitor with IC50 of 127 nM, reduces tumor volume in vivo.(In Vitro):Seclidemstat (72 hours) inhibits SWI/SNF-mutation-dependent tumor cell proliferation with IC50 ranging from 0.013 to 2.819 μM (COV434, BIN67, SCCOHT-1, TOV21G, SKOV3, A427, H522, A549, H1299, G401, G402, HCC15 cells).Seclidemstat (72 hours) promotes endogenous retroviruses (ERVs) expression and activation of IFNβ pathway in SCCOHT cell lines (SCCOHT-1, BIN67, and COV434 cells).Seclidemstat (3 μM) promotes PD-L1 expression in SCCOHT COV 434 pIND 20 BRG1-2.7 cell line.

——

——

SP-2577 | SP2577

Chromatin/Epigenetic

Histone Demethylase

LSD1

Cancer

——

1423715-37-0

450.938

C20H23ClN4O4S

>98% (HPLC)

DMSO: Soluble （ < 1 mg/ml refers to the product slightly soluble or insoluble )

O=C(N/N=C(C1=CC(Cl)=CC=C1O)\C)C2=CC=CC(S(=O)(N3CCN(C)CC3)=O)=C2

N'-[(1E)-1-(5-chloro-2-hydroxyphenyl)ethylidene]-3-(4-methylpiperazine-1-sulfonyl)benzohydrazide

(-20℃)

With Ice Pack

≥ 2 years